Santhera Pharmaceuticals

Kevzara's Covid-19 setback shows need for hard evidence

As investors continue to jump on small sparks of hope in the pandemic pipeline Sanofi and Regeneron inject a dose of reality.

Vertex’s second transformation: Duchenne time

The cystic fibrosis player does deals with Crispr and Exonics to launch itself into a highly competitive rare disease area.

April 05, 2018

Market sees hard path ahead for Gensight

March 05, 2018

Troubled Zinbryta might not be missed in stagnant multiple sclerosis space

February 15, 2018

Santhera becomes third group to buy into novel respiratory mechanism

February 09, 2018

Sarepta contains UK study halt, for now

September 18, 2017

Corrected: Weekly Market Movers: Global Majors & Industry (to 15 Sep 2017)

September 15, 2017

Snippet roundup: Bad news for Sage and Santhera, good tidings for Glaxo and Bayer

September 06, 2017

Sarepta hopes to pull off the same trick twice

August 07, 2017

Interview – Santhera readies muscular dystrophy push

June 27, 2017

Aveo comeback highlights a transatlantic split

Most drugs get the nod in the US before Europe – but there are some cases where the usual trend is reversed.

Load More